Business Description
Island Pharmaceuticals Ltd
ISIN : AU0000138869
Description
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections, public health, or biosecurity threats. The company is following a dual development plan for its assets, ISLA-101 and Galidesivir. Its product candidate, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever viruses, with unmet medical needs. The company operates in a single segment, being research and development activities in Australia and the United States of America.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.89 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 253.84 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 11.7 | |||||
3-Year EPS without NRI Growth Rate | 8.5 | |||||
3-Year FCF Growth Rate | 10.1 | |||||
3-Year Book Growth Rate | -15.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.4 | |||||
Quick Ratio | 8.4 | |||||
Cash Ratio | 7.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -39.2 | |||||
Shareholder Yield % | -5.27 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -3637.61 | |||||
Net Margin % | -3596.33 | |||||
EBITDA Margin % | -3571.56 | |||||
FCF Margin % | -4127.42 | |||||
OCF Margin % | -3356.45 | |||||
ROE % | -118.62 | |||||
ROA % | -108.95 | |||||
ROIC % | -2483.14 | |||||
3-Year ROIIC % | 8257.14 | |||||
ROCE % | -118.56 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 490 | |||||
PB Ratio | 18.15 | |||||
Price-to-Tangible-Book | 33.8 | |||||
EV-to-EBIT | -20 | |||||
EV-to-EBITDA | -20.14 | |||||
EV-to-Revenue | 1319.72 | |||||
EV-to-FCF | -31.85 | |||||
| Price-to-Net-Current-Asset-Value | 33.8 | |||||
| Price-to-Net-Cash | 33.8 | |||||
Earnings Yield (Greenblatt) % | -5 | |||||
FCF Yield % | -3.11 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Island Pharmaceuticals Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.062 | ||
| EPS (TTM) (€) | -0.018 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 77.48 | ||
| 14-Day ATR (€) | 0.012994 | ||
| 20-Day SMA (€) | 0.23015 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 0.192 - 0.338 | ||
| Shares Outstanding (Mil) | 296.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Island Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Island Pharmaceuticals Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Island Pharmaceuticals Ltd Frequently Asked Questions
What is Island Pharmaceuticals Ltd(FRA:7X0)'s stock price today?
The current price of FRA:7X0 is €0.34. The 52 week high of FRA:7X0 is €0.34 and 52 week low is €0.19.
When is next earnings date of Island Pharmaceuticals Ltd(FRA:7X0)?
The next earnings date of Island Pharmaceuticals Ltd(FRA:7X0) is .
Does Island Pharmaceuticals Ltd(FRA:7X0) pay dividends? If so, how much?
Island Pharmaceuticals Ltd(FRA:7X0) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Island to present at World Antiviral Congress 2022 | 2022-11-15 | ||
| Island Pharmaceuticals granted key patent for ISLA-101 in the United States | 2021-05-19 |
Articles on Island Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers